Treatment of aggressive, or progressing indolent peripheral T- and NK-cell neoplasias by combination of fludarabine, cyclophosphamide and doxorubicine

Onkologie

Volumn 24, Issue 2, 2001, Pages 162-164

  Weidmann, E ^a,f   Boehrer, S ^b   Chow, K U ^c   Engels, K ^d   Harder, L ^e   Hinz, T ^a   Janssen, O ^b   Kriener, S ^c   Rummel, M J ^d   Siebert, R ^e   Kabelitz, D ^d   Hansmann, M L ^a   Hoelzer, D ^b   Mitrou, P S ^c  

^a Medizinische Klinik III   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d Abteilung für Immunologie   (Germany)

^e UNIVERSITY OF KIEL   (Germany)

^f UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Cyclophosphamide; Doxorubicine; Fludarabine; Pathophysiology; Peripheral T and NK Cell neoplasias

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE;

AGED; ARTICLE; B CELL LYMPHOMA; CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; NATURAL KILLER CELL LEUKEMIA; PATHOPHYSIOLOGY; STANDARDIZATION; T CELL LEUKEMIA; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; FEMALE; HUMANS; KILLER CELLS, NATURAL; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME; VIDARABINE;

EID: 17744381339     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000050305     Document Type: Article

References (14)

1. Armitage JO, Weisenburger DD New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologie subtypes. J Clin Oncol 199S;16:2780-2795.
2. Lopez-Guillermo A, Cid J, Salar A, Lopez A, Montalban C, Castrillo JM, Gonzalez M, Ribera JM, Brunei S, Garcia-Cône J, Fernandez de Sevilla A, Bosch F, Monserat E Peripheral T-cell lymphomas: Initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. classification. Ann Oncol 199S;9:849-855.
3. Weidmann E Hepatosplenic T-cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990. Leukemia 2000;14:991-997.
4. Matutes E, Brito-Babapulle V, Swansbury J, Ellis J, Morilla R, Dearden C, Sempere A, Catovsky D Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood 1991;78:3269-3274.
5. Loughran TP Clonal disease of large granular lymphocytes. Blood 1993:82:1-14.
6. Coiffier B, Brousse N, Peuchmaur M, Berger F, Gisselbrecht C, Bryon PA, Diebold J Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: A prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. Ann Oncol 1990;1:45-50.
7. Rsher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Click JH, Coltman CA Jr, Miller TP Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced Non-Hodgkin's lymphoma. N Engl J Med 1993:328:1002-1006.
8. Keating MJ Chronic lymphocytic leukemia. Semin Oncol 1999(suppl 14)26:107-114.
9. Hast R, Jacobsson B, Petrescu A, Hjalmar V Successful treatment with fludarabine in two cases of angioimmunoblastic lymphadenopathy with dysproteinemia. Leuk Lymphoma 1999;34:597-601.
10. Armitage JO Peripheral T-cell lymphoma; in Canellos GP, Lister TA, Sklar JL (eds):The Lymphomas. Philadelphia, WB Saunders, 1998, pp 439-448.
11. Schlegelberger B, Zwingers T, Hohenadel K, HennéBruns D, Schmilz N, Haferlach T,Tirier C, Barteis H, Sonnen R, Kuse R, Grote W Significance of cytogenetic findings for the clinical outcome in patients with T-cell lymphoma of angioimmunoblastic lymphadenopathy type. J Clin Oncol 1996;14:593-599.
12. Lepretre S, Buchonnet G, Stamatoullas A, Lenain P, Duval C, d'Anjou J, Callet MP, Tilly H, Bastard C Chromosome abnormalities in peripheral T-cell lymphoma. Cancer Genet Cytogenet 2000;117:71-79.
13. Shimoyama M, Oyama A, Tajima K, Tobinai K, Minato K, Takenaka T, Konda C, Takeyama K, Kohno A Differences in clinicopathological characteristics and major prognostic factors between Blymphoma and peripheral T-lymphoma excluding adult T-cell leukemia/lymphoma. Leuk lymphoma 1993;10:335-342.
14. Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Briere J, Haioun C, Cazals-Hartem D, Bosly A, Xerri L, Tilly H, Berhger F, Bouhabdallah R, Diebold J Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etude des lymphomes de l'Adulte (GELA). Blood 199S;92:76-82.